Varicella Attenuated Live Vaccine Market

SKU: DMPH3053 | Last Updated On: Oct 26 2022 | Available Formats

> Global Varicella Attenuated Live Vaccine Market Expected to reach a high CAGR By 2029: DataM Intelligence

Global Varicella Attenuated Live Vaccine Market is segmented By Product (Monovalent Varicella Vaccine, Combination Varicella Vaccine), By Application (Chickenpox Immunization, Herpes Zoster Immunization, MMRV Immunization), By Provider (Public Provider, Private Provider), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2022-2029

 

Market Overview

[180 Pages Report] The Global Varicella Attenuated Live Vaccine Market is expected to grow at a CAGR during the forecasting period (2022-2029).

Varicella Attenuated Live Vaccine Market - Strategic Insights

Metrics

Details

Market CAGR

5%

Segments Covered

By Product, By Application, By Provider and By Region

Report Insights Covered

Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights.

Fastest Growing Region

Asia Pacific

Largest Market Share 

North America

To Get a Free Sample Click here

Varicella-zoster, also known as Human alphaherpesvirus 3, causes herpes zoster and chickenpox in humans. The infection instigated by this virus can be avoided by using vaccinations that are particularly formulated to provide immunity against the virus. These vaccines vary from each other based on their contents. For instance, the monovalent varicella vaccine comprises only one strain of the virus. In contrast, the combination varicella vaccine includes more than one piece of the virus and offers immunity against more than one virus.

Market Dynamics

Certain factors leading the market growth include the increasing prevalence of candidiasis, the increasing R&D expenditure, and untapped opportunities in the emerging markets. However, the lack of awareness regarding vulvovaginal candidiasis in underdeveloped economies will hamper the market growth during the forecast period.

The expected increase in the prevalence of chickenpox

According to CDC (Centers for Disease Control and Prevention), more than 3.5 million cases of chickenpox, along with 9,000 hospitalizations and 100 mortalities, are averted by chickenpox vaccination in the U.S. This, in turn, contributes to the growth of varicella attenuated live vaccine market. Several companies strengthen their position by driving national programs for support and coordination among federal, local, regional, and international stakeholders, which has improved immunization coverage rates.

Increasing government focus on varicella attenuated live vaccine

The government support is increasing with the rising focus on driving immunization programs to lessen the disease burden impact that aids in the growth of the varicella attenuated live vaccine market. In collaboration with Gavi, WHO, the World Bank, and UNICEF, a few manufacturers are committed to boosting immunization programs and speeding up the introduction of new vaccines. This would contribute to the growth of the varicella attenuated live vaccine market.

COVID-19 Impact Analysis

A decrease in the market value of varicella attenuated live vaccine is expected in 2020, backed by the decline in hospital visits, which also hampered immunization programs' functioning. Therefore, the demand for varicella attenuated live vaccine decreased amid the COVID-19 pandemic, which declined the vaccine's sales in 2020.

Segment Analysis

Based on the application, the varicella attenuated live vaccine market has been classified into Chickenpox Immunization, Herpes Zoster Immunization, MMRV Immunization, and econazole.

The chickenpox Immunization segment contributed a significant share to global varicella attenuated live vaccine market in 2020

Chickenpox immunization contributed the largest varicella attenuated live vaccine market share in 2019, owing to immunization employed with an initial aim of developing immunity against chickenpox. It is highly contagious and is typically spread by direct contact or via air by sneezing and coughing. The illness commonly causes an itchy rash and leads to more than 400 blisters all over the body. Additionally, it causes fussiness, headache, and coughing in the patients.

The varicella attenuated live vaccine market has been classified into monovalent varicella vaccine and combination varicella vaccine based on the product.

Monovalent Varicella Vaccine leads the market throughout the forecast period.

The monovalent Varicella Vaccine segment led the overall market with a share in 2019. It is also expected to foresee rapid growth during the forecast period, as such vaccines demonstrate lesser chances of causing febrile seizures in children than combination vaccines. Besides, easy availability and a broad product portfolio are the other factors that enhance varicella attenuated vaccine market growth.

Geographical Analysis

Based on geography, the study analyzes the varicella attenuated live vaccine market in the global market, including North America, South America, Europe, Asia-Pacific, and the Middle East & Africa.

North America leads the global market throughout the forecast period.

North America dominated the global varicella attenuated live vaccine market with the largest share in terms of value and volume globally, followed by Europe and the Asia Pacific. The US dominated the North American varicella attenuated live vaccine market in 2019. The presence of skilled healthcare professionals and key market players, such as Merck & Co., Inc., are other factors supporting market growth.

Moreover, Asia Pacific is expected to project the fastest growth rate in the varicella attenuated live vaccine market during the forecast period. China dominates the market, whereas India is estimated to exhibit considerable growth in the Asia Pacific varicella attenuated live vaccine market during the forecast period. The gradual rise in vaccination for varicella and the rapidly evolving life science industry augment the market growth in the region.

Competitive Landscape

The varicella attenuated live vaccine market is highly competitive, owing to the large presence of varicella attenuated live vaccine brands. Key varicella attenuated live vaccine players include Bio-Med Pvt. Limited, GlaxoSmithKline PLC, GC Pharma (Green Cross Holdings), Novo Medi Sciences Pvt. Ltd., Emcure Pharmaceuticals Limited, Sanofi SA, Merck & Co. Inc., Mitsubishi Tanabe Pharma Corporation, and Takeda Pharmaceutical Company Limited. The crucial players are adopting new product launches, and expansion strategies for global growth in varicella attenuated live vaccine market.   

Merck & Co. Inc.

Overview: Merck & Co. Inc. is a research-based pharmaceutical company that offers healthcare solutions via its prescription medicines, biologic therapies, vaccines, animal health products. The company sells its products to hospitals, drug wholesalers and retailers, government agencies, and other institutions. It generates over 40.0% of its revenue from the US.  

Product Portfolio: The company's portfolio comprises VARIVAX and ZOSTAVAX.

Why Purchase the Report?

  • Visualize varicella attenuated live vaccine market segmentation composition by product, application, provider, and region, highlighting the critical commercial assets and players.
  • Identify commercial opportunities in the varicella attenuated live vaccine market by analyzing trends and co-development deals.
  • Excel data sheet with thousands of data points of varicella attenuated live vaccine market - level 3 segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Product mapping in excel for the key product of all major market players

Global varicella attenuated live vaccine market report would provide access to an approx: 51 market data tables, 50 figures, and 180 pages.

Target Audience

  • Service Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes

  • Research Professionals
  • Emerging Companies

FAQ

What is the Varicella Attenuated Live Vaccine Market growth?

The market is growing at a CAGR of 5%.

What is Varicella Attenuated Live Vaccine Market size in 2021

The Varicella Attenuated Live Vaccine Market size was valued at USD YY million in 2021.

Who are the key players in Varicella Attenuated Live Vaccine Market?

GlaxoSmithKline PLC, GC Pharma (Green Cross Holdings), Novo Medi Sciences Pvt. Ltd., Emcure Pharmaceuticals Limited.

Trending Topics

Malaria Vaccines Market

Vaccine Market

DNA Vaccines Market

Did not find what you were looking for?Every 7 out of 10 customers request tailored reports. Get yours today!
We collate your requirements.
Our global research team is put into action.
We deliver, and make sure your endeavour is a success!

Buy This Report

20% Discount Applied*



Note*: For "Bundle/Bulk" Subscription of Reports,
please contact: [email protected]

Get your free sample proposal with a single click!

linkedinpinterest